Peginterferon alfa-2b
Regulatory milestones approvals, filings & regulatory actions · 11 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed COVID-19 1 milestone | |||||
| Filed | Other | — | COVID-19 | 2021-04-05 | “Company has applied for an Additional Indication with the DCGI for the use of PegIFN in the treatment of COVID 19.” zyduslife.com ↗ |
| Withdrawn Indication not stated 4 milestones | |||||
| Withdrawn | EU (EMA) | PegIntron | — | 2021-04-21 | europa.eu ↗ |
| Label expansions (7) | US (FDA) | PEGINTRON | — | 2001-08-07 – 2013-12-18 | fda.gov ↗ |
| Approved | US (FDA) | PEGINTRON | — | 2001-01-19 | fda.gov ↗ |
| Approved | EU (EMA) | PegIntron | — | 2000-05-24 | europa.eu ↗ |
Trials 121 · started per year
News releases announcing trial results or a regulatory action · 27
| Date | Issuer | Release |
|---|---|---|
| 2021-04-23 | Zydus Lifesciences Limited | Regulatory Zydus receives Emergency Use Approval from DCGI for the use of Pegylated Interferon alpha-2b, Virafin in treating moderate COVID-19 infection in adults zyduslife.com ↗
Zydus Cadila today announced that the company has received Restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults. |
| 2021-04-05 | Zydus Lifesciences Limited | Regulatory Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19 zyduslife.com ↗
Company has applied for an Additional Indication with the DCGI for the use of PegIFN in the treatment of COVID 19. |
| 2020-12-04 | Zydus Lifesciences Limited | Regulatory Zydus receives approval from DCGI to commence Phase III clinical trials with Pegylated Interferon alpha-2b in India zyduslife.com ↗
Zydus Cadila, today announced that it had received an approval from the Drugs Controller General of India (DCGI) to start the Phase 3 clinical trial in CoVID-19 patients with its biological therapy, Pegylated Interferon alpha-2b, ‘PegiHepTM’. |
| 2020-11-12 | Zydus Lifesciences Limited | Results Zydus successfully completes Phase II clinical trials with Pegylated Interferon alpha2b in India; the Company to start Phase III clinical trials zyduslife.com ↗
Pegylated Interferon alpha – 2b significantly increased viral reduction and reduced the need for supplemental oxygen in moderate COVID-19 patients; the Company will now commence Phase III clinical trials. |
| 2020-08-05 | Zydus Lifesciences Limited | Regulatory Zydus Cadila's Q1 Net profit up by 50% zyduslife.com ↗
Zydus received approvals from COFEPRIS of Mexico for clinical trials of Pegylated Interferon Alpha 2b in COVID 19 patients. |
| 2020-07-17 | Zydus Lifesciences Limited | Regulatory Zydus receives approval from COFEPRIS to conduct clinical trials in Mexico with Pegylated Interferon alpha-2b to treat novel Coronavirus zyduslife.com ↗
Zydus receives approval from COFEPRIS to conduct clinical trials in Mexico with Pegylated Interferon alpha-2b to treat novel Coronavirus |
| 2014-04-09 | Merck Sharp & Dohme LLC | Results Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Naïve Patients with Genotype 1 Infection merck.com ↗
Additionally, new data from PN038, a Phase 2 dose-ranging clinical trial evaluating MK-5172 once-daily with peginterferon alfa-2b and ribavirin (PR, weekly), were presented, evaluating SVR24 in treatment-naïve, non-cirrhotic patients with GT1 infection. |
| 2013-04-24 | Vertex Pharmaceuticals Incorporated | Results Vertex Announces New Data that Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment Among People with Genotype 1 Hepatitis C Who Have the IL28B CC Genotype vrtx.com ↗ |
| 2013-04-23 | Boehringer Ingelheim | Results Boehringer Ingelheim's Faldaprevir-Based Treatment Regimen Achieved Viral Cure in up to 80 per cent of Patients with Hepatitis C in Phase 3 Pivotal Trial(1) prnewswire.com ↗
Boehringer Ingelheim ( Canada ) Ltd. today announced results from the pivotal Phase 3 STARTVerso™1 trial of faldaprevir (BI 201335) † in combination with pegylated interferon and ribavirin (PegIFN/RBV). |
| 2013-04-23 | Merck Sharp & Dohme LLC | Results Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™ merck.com ↗
the rates of sustained viral response (SVR) at week 24 follow-up (SVR24) were 86 percent (55/64) and 92 percent (61/66) for the MK-5172 100 mg plus PR and MK-5172 200 mg plus PR arms |
| 2013-04-23 | Janssen Research & Development, LLC | Results Findings from Two Phase 3 Studies of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients jnj.com ↗
In both studies, 50 percent of patients receiving pegylated interferon and ribavirin alone achieved SVR12. |
| 2013-04-08 | Merck Sharp & Dohme LLC | Results Merck to Present New Data on VICTRELIS® (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM / 2013 EASL Annual Meeting merck.com ↗
High Sustained Viral Response at 12- and 24-week follow-up of MK-5172 with Pegylated Interferon alfa-2b and Ribavirin (PR) in HCV Genotype 1 Treatment-naïve Non-cirrhotic Patients. |
| 2012-11-10 | Merck Sharp & Dohme LLC | Results Merck Reports New Phase III Analyses on Anemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy, Including Cirrhotic Patients merck.com ↗
SVR rates were generally similar regardless of when patients began ribavirin dose reduction, the number of steps of ribavirin dose reduction, or the lowest ribavirin dose of 400 to 1,000 mg/day received for at least 14 days for anemia management. |
| 2012-11-10 | Merck Sharp & Dohme LLC | Results Interim Phase II Data of Merck’s Investigational MK-5172 in Combination Therapy in Chronic Hepatitis C Virus Genotype 1 Infection to be Presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting merck.com ↗
The MK-5172 regimens had rates of cEVR ranging from 82.8 to 93 percent, versus the control of 74.2 percent. |
| 2012-04-19 | Merck Sharp & Dohme LLC | Results Merck Reports Phase III Study Results Evaluating Anemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy merck.com ↗
The rates of SVR were 71 percent for both groups: those patients whose anemia was managed by ribavirin dose reduction (178/249) and those patients whose anemia was managed by the addition of erythropoietin (EPO) (178/251). |
| 2012-04-18 | Vertex Pharmaceuticals Incorporated | Results Vertex Advances INCIVEK™ (telaprevir) and Broad Portfolio of Medicines in Development With Goal of Further Expanding and Improving Treatment for People With Hepatitis C vrtx.com ↗
Subanalysis of Phase 2 data shows 12 weeks of INCIVEK combination treatment resulted in a viral cure (SVR) for 100% of people with hepatitis C who had the IL28B CC genotype |
| 2012-03-06 | Merck Sharp & Dohme LLC | Results Results from Investigational Studies with VICTRELIS™ (boceprevir) Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1 merck.com ↗
In the study, a higher percentage of patients receiving VICTRELIS in combination with peginterferon alfa-2b and ribavirin had undetectable hepatitis C virus (HCV-RNA) 12 weeks after treatment ended (sustained virologic response-12 1 or SVR-12) than patients receiving peginterferon alfa-2b and ribavirin alone. |
| 2012-01-18 | Bristol-Myers Squibb | Results First Hepatitis C Treatment Data Demonstrating Proof of Principle with Direct-Acting Antiviral-only Therapy Published bms.com ↗
The study also demonstrated that 100 percent (10/10) of these difficult-to-treat patients dosed with quadruple therapy containing daclatasvir and asunaprevir in combination with PEG-Interferon alfa and ribavirin achieved SVR12. |
| 2011-11-05 | Merck Sharp & Dohme LLC | Results Interim Data for Merck’s VICTRELISTM (boceprevir) in Prior Null Responder Patients with Chronic Hepatitis C Genotype 1 to be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting merck.com ↗
In this interim analysis, 38 percent (16/42) of prior null responders achieved a sustained virologic response (SVR)1 when treated with VICTRELIS in combination with P/R. |
| 2011-10-20 | Merck Sharp & Dohme LLC | Results Interim Phase IIb Data for Merck’s VICTRELIS™ (boceprevir) in Patients Coinfected with Chronic Hepatitis C and HIV-1 Presented at the Infectious Diseases Society of America (IDSA) 2011 Annual Meeting merck.com ↗
These interim results are being presented for the first time in a late-breaker oral presentation at the Infectious Diseases Society of America (IDSA) 2011 annual meeting in Boston. |
| 2011-04-02 | Bristol-Myers Squibb | Results Investigational Compound PEG-Interferon Lambda Achieved Higher Response Rates with Fewer Flu-Like and Musculoskeletal Symptoms and Cytopenias Than PEG-Interferon Alfa in Phase IIb Study of 526 Treatment-Naive Hepatitis C Patients bms.com ↗ |
| 2011-03-31 | Bristol-Myers Squibb | Results Investigational Direct-Acting Antiviral BMS-790052 Plus PEG-Interferon Alfa and Ribavirin Achieved Up to 92% Sustained Virologic Response in Phase II Dose-Ranging Study of Treatment-Naïve Hepatitis C Patients bms.com ↗ |
| 2010-11-01 | Bristol-Myers Squibb | Results Bristol-Myers Squibb Posts New Data on Combination of Investigational Compounds BMS-790052 and BMS-650032 for the Treatment of Chronic Hepatitis C bms.com ↗
The data were presented today at the 61 st Annual Meeting of the American Association for the Study of the Liver Diseases in Boston. |
| 2009-10-31 | Vertex Pharmaceuticals Incorporated | Results More than 80% of Hepatitis C Patients Treated in Study C208 Achieved an SVR with Telaprevir-Based Regimens vrtx.com ↗
For the majority of patients, these SVR rates were obtained with a 24-week telaprevir-based regimen. |
| 2009-04-25 | Vertex Pharmaceuticals Incorporated | Results Telaprevir Data Presented at EASL Show Unprecedented SVR Rates in HCV Treatment-Failure Patients in PROVE 3 Study vrtx.com ↗
In comparison, SVR rates were achieved by 14% of patients randomized to receive 48 weeks of peg-IFN and RBV alone. |
| 2006-01-09 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference vrtx.com ↗
In this study, patients receiving a combination of VX-950 dosed with peg-IFN achieved a median 5.5 log10 reduction in HCV RNA at 14 days. |
| 2004-04-16 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches vrtx.com ↗
New data for proprietary investigational antiviral therapies for hepatitis C virus (HCV) infection being developed by Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) were presented today at the Annual Meeting for the European Association for the Study of the Liver (EASL) in Berlin, Germany. |
All press releases naming this drug 32 releases
Evidence & citations 34 cited values
Every value below carries the sentence it was read from. 189 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | peginterferon alfa-2b | “This is a study to evaluate the safety and tolerability of peginterferon alfa-2b (PegIFN alfa-2b) as adjuvant treatment in Japanese participants with malignant melanoma after...” NCT01636960 ↗108“Patients with mild hepatitis C recurrence (fibrosis stage F0 to F2, n = 54) were randomized to no treatment (group A, n = 27) or peginterferon alfa-2b/ribavirin for 48 weeks...” PMID 17484872 ↗ Mar 2007 “Lowering Viral Load With Nucleos(t)Ide Analogues Prior to Peginterferon Alfa-2b Treatment to Increase Sustained Response in HBeAg-positive Chronic Hepatitis B - a Pilot Study” NCT00883844 ↗ “This is a Phase 3b/4, prospective, open-label, randomized, multicenter study of peginterferon alfa-2b plus ribavirin in participants with chronic hepatitis C, genotype 1.” NCT00493805 ↗ “PegIntron (peginterferon alfa-2b) administered at a dose of 1.5 mcg/kg subcutaneously (SC) once a week (QW) for up to 48 weeks” NCT00039871 ↗ “A Parallel Phase I/II Study of Low Dose Decitabine (5-Aza-Deoxycytidine) With Peginterferon Alfa-2b in Advanced Melanoma” NCT00791271 ↗ “Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: a randomized trial.” PMID 25200354 ↗ Aug 2014 “Peginterferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications.” NCT01285050 ↗ “Peginterferon Alfa-2A 180 micrograms/week or Peginterferon Alfa-2B 180 micrograms/week, for at most 96 weeks.” NCT03801538 ↗ “peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.” NCT02908763 ↗ “peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.” NCT02893124 ↗ |
| Known as | PEG | “Arm 1A: PegIntron (PEG) + Ribavirin (RBV)” NCT00160251 ↗1“Peginterferon alfa-2b (PEG)” NCT01390844 ↗ |
| Known as | PEG (pegylated)-Intron | “The drug used in this study is PEG (pegylated)-Intron.” NCT00396019 ↗ |
| Known as | PEG IFN alfa 2b : Peg Intron | “PEG IFN alfa 2b : Peg Intron” NCT01457937 ↗ |
| Known as | PEG IFN-α | “Patients receive PEG-interferon alfa-2b (PEG IFN-α) subcutaneously (SC) on days 1, 8, 15, and 22.” NCT00085384 ↗ |
| Known as | Peg interferon alfa 2b (Peg Intron) | “Peg interferon alfa 2b (Peg Intron)” NCT00207363 ↗ |
| Known as | Peg-alpha interferon | “Peg-alpha interferon (Peg-Intron)” NCT00050531 ↗ |
| Known as | PEG-IFN | “We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon-α2b (PegIFN) after 3 months (M3).” PMID 27133821 ↗ May 20167“peginterferon alfa-2b (PEG-IFN) and ribavirin (RBV) for difficult-to-treat patients” PMID 22239511 ↗ Nov 2011 “versus pegylated interferon (Peg-IFN) in naïve chronic hepatitis B patients.” PMID 30133478 ↗ Aug 2018 “Peg-Interferon (PegIFN) alfa 2b by subcutaneous injection 1,5 µg/kg/week” NCT01335529 ↗ “PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen” NCT00135798 ↗ “peginterferon alfa-2b (PEG-IFN) subcutaneously” NCT00687544 ↗ “Peginterferon alfa-2b (Peg-IFN)” NCT01440595 ↗ “peginterferon-α-2b (PEG IFN)” PMID 25196718 ↗ Nov 2014 |
| Known as | PEG-IFN alfa-2b | “The findings from this study will aid in the understanding of whether HIV infection affects HCV antiviral and host responses to combination therapy using BOC/peg-IFN alfa-2b/RBV.” NCT01443923 ↗13“The control group received 48 subcutaneous injections of Peg-IFN alfa 2b, 180 μg per dose, every week, for 48 consecutive weeks.” PMID 30133478 ↗ Aug 2018 “This study will use a new, longer acting form of IFN called PEG-IFN alfa-2b.” NCT00015652 ↗ “PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day)” NCT01457937 ↗ “Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV)” NCT01606800 ↗ “Pegylated interferon (PEG-IFN) alfa-2b plus ribavirin (RBV)” PMID 20189674 ↗ Feb 2010 “Peginterferon alfa-2b (pegIFN alfa-2b)” NCT01366638 ↗ |
| Known as | PEG-IFN alpha-2b | “Participants who have chronic hepatitis C genotype 1 monoinfection (N=50) or coinfection with HIV-1 (N=50), and who are na(SqrRoot) ve to IFN-based HCV treatment, will receive...” NCT01443923 ↗2“To characterize the ocular changes associated with peginterferon alpha 2b (peg-IFN alpha-2b) and ribavirin therapy for chronic hepatitis C infection in HIV co-infected individuals.” PMID 15316341 ↗ Sep 2004 “1.5 μg/kg weekly dose of subcutaneous PEG-IFN alpha-2b (PegIntron A, Schering-Plough, Osaka, Japan)” NCT00956982 ↗ |
| Known as | PEG-IFN α-2b | “This randomized, prospective, parallel-group clinical trial compared the efficacy and safety of pegylated interferon α-2a (PEG-IFN α-2a) plus ribavirin and PEG-IFN α-2b plus...” PMID 21281434 ↗ Jan 20119“In the pilot NCT01935089 trial, we tested whether pegylated interferon alpha2b (Peg-IFN-α2b) with antiretroviral therapy (ART) was safe and could impact HIV and immune measures...” PMID 33323024 ↗ Jan 2021 “EPIC(3) included a prospective trial assessing long-term peginterferon alfa-2b (PegIFNα-2b) maintenance therapy in patients with METAVIR fibrosis scores (MFS) of F2 or F3 who...” PMID 23159770 ↗ Nov 2012 “In the adjuvant setting for malignant melanoma, interferon (IFN)-α-2b and pegylated (PEG) IFN-α-2b were approved in several countries including the USA before these were...” PMID 27087489 ↗ Oct 2016 “In this open-label pilot study, 29 patients with CHC who failed previous therapy with (peg)IFNα/ribavirin were treated with SAMe, betaine, pegIFNα2b and ribavirin.” PMID 21079746 ↗ Nov 2010 “The pegylated interferon (Peg-IFN) group will receive ETV for the first 48 weeks, followed by combination therapy with Peg-IFN α-2b for the remaining 48 weeks” NCT07345624 ↗ “Pegylated Interferon alpha 2b (peg-IFN-α2b) will be administered weekly via subcutaneous route.” NCT03588715 ↗ “Group B received PegIFNα-2b monotherapy for 48 weeks” NCT06900166 ↗ “Peginterferon Alfa (PegIFN α)-2b/Ribavirin (Riba)” NCT01457937 ↗ “pegylated interferon α-2b (Peg-IFN-α2b)” NCT07183293 ↗ |
| Known as | Peg-IFN-α-2β | “peginterferon alfa-2β (Peg-IFN-α-2β) combined with nucleos(t)ide analogues (NAs)” NCT07553767 ↗ |
| Known as | peg-IFN2b | “In this study we sought to characterize the relationship between several pharmacokinetic and pharmacodynamic parameters and virologic responses among HIV/hepatitis C virus...” PMID 19898214 ↗ Nov 2009 |
| Known as | PEG-INF | “Participants who achieved RVR after 4 weeks of PEG-INF alfa-2b plus RBV treatment were randomized to receive either 20 or 44 weeks of continued therapy, for a total of 24 or 48...” NCT01606800 ↗ |
| Known as | PEG-INF alfa-2b | “Participants who achieved RVR after 4 weeks of PEG-INF alfa-2b plus RBV treatment were randomized to receive either 20 or 44 weeks of continued therapy, for a total of 24 or 48...” NCT01606800 ↗ |
| Known as | PEG-interferon | “RATIONALE: Peginterferon (PEG-interferon) alfa-2b may stop the growth of cancer by stopping blood flow to the tumor.” NCT00049530 ↗1“Peginterferon alpha-2b 1.5 μg/kg per week s.c.for 48 weeks” NCT01532843 ↗ |
| Known as | PEG-Intron | “This study will investigate the intracellular exposure to active ZDV metabolites prior to and after treatment with Rebetron or treatment with PEG-Intron (pegylated interferon)...” NCT00059358 ↗44“Recently a new formulation of Interpheron alpha2b is available. Conjugated with polietilenglicol (Pegintron) that need only one dose weekly and has not been tested in MM.” NCT01325896 ↗ “each dosage schedule with or without the co-administration of pegylated interferon-α (Pegintron 1 μg/kg s.c.) at the day of vaccine administration” NCT01923116 ↗ “Phase II Trial of ZD1839 (IRESSA®) and Pegylated Interferon Alfa 2b (PEG-Intron™) in Unresectable or Metastatic Renal Cell Carcinoma” NCT00467077 ↗ “Patients receive peginterferon alfa-2b (Pegintron®) combined with first-line nucleos(t)ide analogues (TDF/TAF/TMF)” NCT07553767 ↗ “Peginterferon alfa-2b (12 kD) [PEG-Intron] at a dosage of 1.5 μg/kg SC once weekly” NCT00087607 ↗ “A Phase I Trial of Peginterferon Alfa-2b (PEG-Intron) for Plexiform Neurofibromas” NCT00253474 ↗ “Induction PEG-Interferon alfa-2b (PEG-Intron) and Ribavirin (Rebetol)” NCT00207363 ↗ “Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)” NCT00511121 ↗ “PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen” NCT00135798 ↗ “Peginterferon alfa-2b (PegIntron, SCH 54031)” NCT00686790 ↗ |
| Known as | PEG2b | “peginterferon alfa-2b (PEG2b) (SCH 54031)” NCT00104052 ↗1“Peginterferon alfa-2b (PEG2b)” NCT01023035 ↗ |
| Known as | Peginterferon Alfa (PegIFN α)-2b | “Peginterferon Alfa (PegIFN α)-2b/Ribavirin (Riba)” NCT01457937 ↗ |
| Known as | PegInterferon alpha 2b | “standard dosages of PegInterferon alpha 2b and weight-based dosages of ribavirin” NCT01121705 ↗2“Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV)” NCT01606800 ↗ “Peginterferon alpha-2b 1.5 μg/kg per week s.c.for 48 weeks” NCT01532843 ↗ |
| Known as | peginterferon-α-2b | “This trial is a part of ZhuFeng Project (The Clinical Cure Project of Chronic Hepatitis B in China; ClinicalTrials.gov, identifier: NCT04035837) and a part of E-Cure Study...” PMID 40390028 ↗ May 20251“peginterferon-α-2b (PEG IFN)” PMID 25196718 ↗ Nov 2014 |
| Known as | PegIntron A | “1.5 μg/kg weekly dose of subcutaneous PEG-IFN alpha-2b (PegIntron A, Schering-Plough, Osaka, Japan)” NCT00956982 ↗ |
| Known as | Pegylated interferon alfa-2b | “An Open-Label, Single-arm, Multicenter Phase I Study of SCH 54031 (Pegylated Interferon Alfa-2b) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (Protocol...” NCT01636960 ↗1“Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week” NCT01606800 ↗ |
| Known as | pegylated interferon alpha2b | “In this study we sought to characterize the relationship between several pharmacokinetic and pharmacodynamic parameters and virologic responses among HIV/hepatitis C virus...” PMID 19898214 ↗ Nov 200924“In the pilot NCT01935089 trial, we tested whether pegylated interferon alpha2b (Peg-IFN-α2b) with antiretroviral therapy (ART) was safe and could impact HIV and immune measures...” PMID 33323024 ↗ Jan 2021 “Eligible patients were treated with pegylated interferon alpha-2b (Peg Intron®; Schering-Plough (Brinny) Company, Innishannon, County Cork, Ireland)” NCT02634294 ↗ “Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.” PMID 27087489 ↗ Oct 2016 “pegylated interferon alpha 2b 1.5 mg/kg/week sc plus weight-adjusted ribavirin po for 48 weeks.” NCT01529073 ↗ “plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week” NCT03483987 ↗ “Pegylated-Interferon-alpha2b (SylatronTM)” NCT01502696 ↗ |
| Known as | pegylated interferon α-2b | “We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon-α2b (PegIFN) after 3 months (M3).” PMID 27133821 ↗ May 201611“patients received PEGylated-interferonα2b (1.5 μg/kg/week)+ ribavirin (800-1400 mg/day) alone until W4 and with BOC(800 mgTID) until W48.” PMID 27077673 ↗ Feb 2016 “pegylated interferon α-2b (Peg-IFN-α2b)” NCT07183293 ↗ “Entecavir + Pegylated interferon α-2b” NCT07345624 ↗ |
| Known as | pegylated interferon-α | “each dosage schedule with or without the co-administration of pegylated interferon-α (Pegintron 1 μg/kg s.c.) at the day of vaccine administration” NCT01923116 ↗ |
| Known as | PGI | “Pegylated Interferon Alpha-2b (PGI)” NCT00525031 ↗ |
| Known as | SCH 054031 | “Peginterferon alfa-2b (SCH 054031)” NCT00724620 ↗1“Peginterferon alfa-2b (SCH 054031)” NCT00687544 ↗ |
| Known as | SCH 54031 | “An Open-Label, Single-arm, Multicenter Phase I Study of SCH 54031 (Pegylated Interferon Alfa-2b) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (Protocol...” NCT01636960 ↗5“Peginterferon alfa-2b (PegIntron, SCH 54031)” NCT00686790 ↗ “PegIntron (peginterferon alfa-2b; SCH 54031)” NCT00081770 ↗ “peginterferon alfa-2b (SCH 54031)” NCT00049842 ↗ “peginterferon alfa-2b (SCH 54031)” NCT00048724 ↗ “Peginterferon alfa-2b (SCH 54031)” NCT00910624 ↗ |
| Known as | Sylatron | “To estimate the 1-year disease stabilization rate associated with the use of Sylatron (peginterferon alfa-2b) in patients with progressive unresectable or recurrent...” NCT01964300 ↗ |
| Known as | SylatronTM | “Pegylated-Interferon-alpha2b (SylatronTM)” NCT01502696 ↗ |
| Action | Inhibit | “Interferon-alfa inhibits HIV replication in vitro” NCT00006325 ↗ |
| Modality | Protein / enzyme biologic | “Peg Interferon Alpha-2B/PEG-Intron” NCT00037882 ↗ |
| Route | Subcutaneous | “one of four doses of PEG-IFN or PEG-IFN placebo administered subcutaneously once per week” NCT00005012 ↗ |